Peptide Comparison
PACAP-38vsBPC-157
Neuroprotective polypeptide with potent anti-inflammatory and cytoprotective properties discovered in 1989
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
PACAP-38
5 pmol/kg/min–20 pmol/kg/min mg
BPC-157
250–500 mcg
Frequency
PACAP-38
Once daily
BPC-157
Once daily
Administration
PACAP-38
Intravenous infusion
BPC-157
Subcutaneous injection
Cycle Length
PACAP-38
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
PACAP-38
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
PACAP-38
Strong human trials (Phase 3 or FDA approved)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Neuroprotection
Anti-Inflammatory
Migraine Research
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
PACAP-38
Molecular Formula
C203H331N63O53S
Molecular Weight
~4534 Da
Half-Life
Very short plasma half-life (minutes); rapid enzymatic degradation
Bioavailability
IV: systemic; Intranasal: direct CNS access bypassing BBB; poor oral bioavailability
CAS Number
137061-48-4
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
PACAP-38
BPC-157
Applications
Best
suited for
PACAP-38
Neuroprotection research
PACAP-38 is particularly well-suited for individuals focused on neuroprotection research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Stroke and traumatic brain injury investigation
PACAP-38 is particularly well-suited for individuals focused on stroke and traumatic brain injury investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Migraine pathophysiology studies
PACAP-38 is particularly well-suited for individuals focused on migraine pathophysiology studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory mechanism research
PACAP-38 is particularly well-suited for individuals focused on anti-inflammatory mechanism research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
PACAP-38
Common
- Flushing
- Tachycardia
- Gastrointestinal Effects
- Transient Warmth Sensation
Uncommon
- Headache and Migraine Triggering
- Hypotension
Serious
- Systemic Hypotension and Cardiovascular Effects
- Systemic Inflammatory Activation
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
PACAP-38
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
PACAP-38 shows good tolerability in Phase II trials for migraine and pain conditions with minimal serious adverse events at IV doses of 2-6 mcg/kg. Primary side effects are transient flushing and headache (10-15% of subjects), likely related to vasodilation. Cardiovascular effects include mild heart rate increase and blood pressure changes, monitored in clinical settings. No carcinogenicity or teratogenicity in animal models; limited long-term safety data in humans.
Contraindications
- xActive migraine or headache disorder (PACAP-38 is a potent migraine trigger)
- xUncontrolled hypotension or cardiovascular instability
- xNot approved for clinical use outside research settings
- xInsufficient data for pregnancy and lactation safety
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose PACAP-38 if...
- Neuroprotection research
- Stroke and traumatic brain injury investigation
- Migraine pathophysiology studies
- Anti-inflammatory mechanism research
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health